A combination of presurgical Zejula and Jemperli showed promising treatment responses in certain patients with ER-positive, ...
GSK’s FIRST-ENGOT-OV44 phase III clinical trial of Zejula and Jemperl in first line advanced ovarian cancer meets primary endpoint: London Saturday, December 21, 2024, 09:00 Hrs ...
This week's health news featured pivotal developments in pharmaceutical trials. GSK's cancer drug combo showed promising ...
Jemperli combo met its primary endpoint in a trial investigating the drugs in first-line advanced ovarian cancer, but missed ...
In one of the final steps before a marketing authorization decision by the European Medicines Agency, it recommended ...
UK pharma major GSK today released mixed headline results from the FIRST-ENGOT-OV44 Phase III trial evaluating Zejula ...
Medpage Today on MSN10h
No Seed Oil-Colon Cancer Link; Avoiding Prostate Biopsy; Top Cancer AdvancesA diet low in omega-6 and enriched with omega-3 fatty acids and fish oil for prostate cancer patients on active surveillance ...
GSK plc (GSK, GSK.L) reported headline results from the FIRST-ENGOT-OV44 phase III trial evaluating Zejula and Jemperli in first line ...
GSK (GSK) announced that the US Food and Drug Administration, FDA, has granted Breakthrough Therapy Designation, BTD, for ...
London: GSK plc has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for ...
GSK (GSK) announced the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, has recommended expanding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback